The protein-drug interaction map suggested that MAPK signaling pathway inhibitors, including ROCK inhibitors (Fasudil, Y-39983 and Ripasudil), MEK inhibitors (Trametinib, TAK-733, Selumetinib, Ro-5126766, Refametinib, Pimasertib and PD-325901), and mTOR inhibitors (Sapanisertib, OSI-027) were associated with a tightly connected network that could potentially mediate therapeutic effects in AML (Figure 6C). Here, MAP2K7 is linked to acute myeloid leukemia.